Search Results

Despite having an impressive roster of high-profile supporters, including AbbVie, BMS, J&J, Novartis and Pfizer, PARP-focused Ribon has called it quits after nearly a decade in business.

Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim.

Ribon Therapeutics today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.

Ribon Therapeutics announced the closing of a $65 million financing.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced in a late-breaking presentation, compelling preclinical data for RBN-3143, a novel, orally administered, first-in-class inhibitor of PARP14 with potential in a range of inflammatory diseases.

Ribon Therapeutics today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.

Ribon Therapeutics today announced that it initiated the healthy volunteer portion of its Phase 1, first-in-human, single ascending dose and multiple ascending dose (SAD/MAD) safety and pharmacokinetic study of RBN-3143.

Ribon Therapeutics today announced it has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.